Kymera IPO Presentation Deck

STAT3 Biology and Degrader Rationale . STAT3 is a traditionally largely undrugged transcription factor activated through cytokine and growth factor receptors via JAKS and non-JAKS mediated mechanisms High degree of validation of JAK-STAT pathway in oncology and immuno-oncology supported also by numerous publications - STAT3 plays a role in tumor biology, evasion of immune surveillance and inflammation/fibrosis - No known drugs specifically affect STAT3 broadly across all relevant cell types . First in class opportunity to address STAT3 driven pathology across large and diverse indications KYMERA Indications/Timeline Hematological Malignancies/Solid Tumors and Autoimmune/Fibrosis Current: Preclinical development Expected IND submission: 2H 2021 Expected P1: 2H21 IL-6 IL-6R JAK JAK GPRC JAK TLRs JAK STAT3 STAT3 STAT3 STAT3 ❤ JAK TYK2

View entire presentation